This newsletter presents you the best read sessions:
1. Podcast with Prof. Hatem A. Azim about fertility preservation and assisted reproductive technologies in
breast cancer patients interrupting endocrine therapy to attempt pregnancy
2. Adding tucatinib to T-DM1 significantly delays disease progression in patients with HER2+ locally
advanced/metastatic breast cancer
3. Pembrolizumab plus neoadjuvant chemotherapy, followed by adjuvant pembrolizumab after surgery as
a standard of care for patients
4. Datopotamab deruxtecan superior to chemotherapy in patients with endocrine resistant HR+/HER2-
advanced breast cancer
5. Adding pembrolizumab to neoadjuvant chemotherapy improves pCR rates across diverse subgroups in
ER+/HER2- breast cancer